Stanford Multiple Sclerosis and Neuroimmunology Program
Stanford Multiple Sclerosis and Neuroimmunology Program Overview
The Stanford Neuroimmunology Program specializes in the diagnosis, treatment, research and education of immune-mediated diseases of the human nervous system, including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, transverse myelitis, optic neuritis, MOGAD, stiff person syndrome, and the broadening range of autoimmunity manifest with neurologic end-organ effect. Clinic care is provided at our interdisciplinary Stanford Neuroscience Health Center, designed for optimized patient access and convenience according to a patient-centric model of comprehensive holistic care. The SNHC offers on site imaging, infusion Center, laboratory services, neuro-rehabilitation, neuropsychology, neurodiagnostics and specialty-level clinical care under one roof. Our program is committed to the research, investigation and discovery of the conditions we treat. Our Clinical Trials team is embedded on site to optimize advisory services, assessment, consent and recruitment in clinical trials; and our clinical efforts are interwoven in collaboration with world-renowned Stanford scientists to offer enterprising translational research. We share this paradigm disruptive work and study with our subspecialty Fellows, Neurology residents, and Stanford University School of Medicine students in our nationally acclaimed teaching programs, with a sincere and abiding commitment to career mentorship, to train tomorrow’s leaders in this vital and burgeoning subspecialty.
Multiple Sclerosis Center Patient Care
Using a collaborative decision-making approach, we work with the patient to find a treatment plan that optimizes his or her disease course and wellness. Our MS specialists and researchers also are involved in a number of studies to understand the MS disease course and improve MS disease management.
Stanford Welcomes our New Neuroimmunology Fellows
Stanford is proud to welcome our 2021-2022 Fellows! Dr. Jamie McDonald will be returning for her Senior Fellowship year with us as Dr. Neda Sattarnezhad joins us following successful completion of her Neurology residency at the University of Illinois.
Oscar Salvatierra Award
Congratulations to Jeffrey Dunn, MD, inaugural award winner of the Oscar Salvatierra Award for Exceptional Service to Stanford medical students and the Stanford University School of Medicine. Dr. Dunn built the Neurology clerkship into a model of national excellence and the highest rated clerkship in the SOM for more than a decade, inspiring more than a thousand medical students during his tenure.
Stanford MS Center certified by the Consortium of MS Centers
The Stanford Multiple Sclerosis Center was awarded ongoing certification for 2021 as a member Center in good standing with the highly esteemed Consortium of Multiple Sclerosis Centers. Stanford's active membership in the CMSC enables Stanford to continue in its role of national leadership in medical and nursing care in the field of MS.
What we can learn from COVID-19 in kids
Stanford Professor of Neurology & Neurological Sciences, Lawrence Steinman, MD, researches what we can learn from COVID-19 in kids in a new paper published in Proceedings of the National Academy of Sciences.
Welcome to Issue 4 of The BIG Brief — a periodic digest of what is top of mind at Project BIG. As you read through the achievements of the team and the promising research underway, despite all the challenges and hardships of this past year, please consider whether you will renew your support of Project BIG for the 2021 year. Our mission is to unlock the cause and cure for MS and other neurological and autoimmune diseases through a unique clinician-scientist collaboration across disciplines. The BIG Brief provides a snapshot of their worlds as well as a curated collection of articles that have captured our team's attention.
Stanford MS Center Launches COViMS Registry
As a NARCRMS member site, and together with the Consortium of MS Centers (CMSC) and the National MS Society (NMSS), Stanford has joined efforts to launch the COVID-19 Infections in MS & Related Diseases (COViMS) registry. COViMS will capture information on outcomes of people with MS and other CNS demyelinating diseases (Neuromyelitis Optica and MOG antibody disease) who have developed COVID-19 in North America (Canada, Mexico & US). This will help our understanding of this disease and its effects and risks specifically pertaining to our clientele, gathering information which can contribute to a safer tomorrow for the patients we care for.
Antibody testing not recommended to assess immunity for COVID: FDA
National MS Society COVID-19 Information
- What you need to know about COVID-19: Consensus information vetted and published by the National MS Society.
- Guidelines for MS Treatments in the time of COVID-19: Consensus guidelines for the use of disease modifying therapies have been developed by the National Medical Advisory Committee of the National MS Society. These guidelines are listed here.